ReviewJournal of kidney cancer and VHL2017
Imaging of Renal Medullary Carcinoma.
Review in Journal of kidney cancer and VHL, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Renal medullary carcinoma: a systematic review of clinical and radiological findings.International urology and nephrology · 2026Pooled it
- Computed tomography and magnetic resonance imaging characteristics of renal cell carcinoma: Differences between subtypes and clinical evaluation.Journal of clinical imaging science · 2025Review
- Diagnostic challenges of renal medullary carcinoma and the role for cytologic assessment: Case report and literature review.Journal of clinical laboratory analysis · 2023Review
- Decreased cross-sectional muscle area in male patients with clear cell renal cell carcinoma and peritumoral collateral vessels.World journal of radiology · 2022Article
- Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma.Clinical genitourinary cancer · 2021Article
- Article
- Increased visceral adipose tissue in male patients with non-clear cell renal cell carcinoma.La Radiologia medica · 2020Article
- Renal medullary carcinoma and its association with sickle cell trait: a case report and literature review.Current oncology (Toronto, Ont.) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal medullary carcinoma (RMC) is a rare, highly aggressive tumor recognized as an independent pathological entity. African-descent adolescents and young adults with sickle cell hemoglobinopathy are the most affected groups. This rare subtype of renal cell carcinoma has its own morphogenetic and pathological characteristics. The major clinical manifestations include gross hematuria, abdominal or flank pain, and weight loss. The prognosis is very poor, with 95% of cases diagnosed at an advanced stage of the disease. In this review, we summarize the morphologic and dynamic characteristics of RMC under various imaging modalities such as ultrasound, computed tomography, and magnetic resonance. Differential diagnosis and management strategies are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.